Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NKTX vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NKTX Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 2–3 Matrix Metrics)

NKTX Overall Winner 6-Pillar Tally: NKTX 2 – 1 ANNX (3 Tie) Matrix Metrics: NKTX 2 – 3 ANNX

As of Nov 17, 2026, Nkarta, Inc. (NKTX) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). NKTX carries a Unified Composite Score of 57.4/100 (HOLD) at $1.24 (N/M Forward P/E, 0.0% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: NKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NKTX vs ANNX
NKTX NASDAQ Head-to-Head Winner
Nkarta, Inc. Common Stock
Pharmaceutical Preparations
$1.24
+2.48% 1D
Market Cap $85.2M
TTM Revenue $385
Forward P/E N/M
Beta / 30D Vol 1.86β · 114% Vol
Unified Composite Score
57.4 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 70.0 Mom 74.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $1.56 · SMA50: $2.13
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.69β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (NKTX 2 – 1 ANNX)

Columns: Metric · NKTX · ANNX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $385 N/A
Market Cap $85.2M $747.8M
3. Profitability & Quality NKTX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.6% -130.8%
4. Balance Sheet & Cash Flow ANNX
Cash Generation (TTM) -$94M -$190M
Cash Flow Margin N/A N/A
Net Cash / Leverage $49M Net Debt (0.30x D/E) $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NKTX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 0.0% (<1st %ile) 569.3% (100th %ile)
Put/Call OI Skew N/A 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NKTX (2) vs ANNX (3)
Institutional Metric NKTX ANNX Criterion Row Edge
Market Capitalization
Scale
$85.2M $747.8M Larger Scale ANNX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.6% -130.8% Higher ROE NKTX
52-Week Range Position
Momentum
5% ($1–$4) 18% ($3–$7) Stronger Trend ANNX
Beta / 30D Volatility
Risk Regime
1.86β · 114% Vol 1.69β · 63% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
57.4 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite NKTX
Trailing 12M Revenue (USD)
Operating Scale
$385 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$94M ($49M Net Debt (0.30x D/E)) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANNX +16.05 pp
NKTX: -29.14% · ANNX: -13.09%
3M Horizon ANNX +14.54 pp
NKTX: -51.18% · ANNX: -36.64%
6M Horizon ANNX +24.71 pp
NKTX: -53.73% · ANNX: -29.02%
1Y Horizon ANNX +62.29 pp
NKTX: -33.69% · ANNX: +28.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NKTX vs ANNX. Trailing 12-month operating profitability (NKTX 0.0% vs ANNX 0.0%) and valuation multiples (NKTX N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NKTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$385
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.6% · N/M
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NKTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact NKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $85.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NKTX vs ANNX Key Questions & Quantitative Answers

As of Nov 17, 2026, Nkarta, Inc. (NKTX) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). NKTX carries a Unified Composite Score of 57.4/100 (HOLD) at $1.24 (N/M Forward P/E, 0.0% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: NKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NKTX and ANNX split Growth & Scale metrics: NKTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $385 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NKTX generates $385 in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, NKTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

NKTX and ANNX trade at balanced relative valuation multiples. NKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NKTX (-46.6% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, NKTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 114% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.